Clinical evaluation of ketotifen after eight weeks of administration for perennial nasal allergy.

概要

論文の詳細を見る
Ketotifen, an anti-allergic drug, was administered orally to 22 patients with perennial nasal allergy twice a day (2mg/day) for 8 weeks, and the following results were obtained:1) The overall improvement rate was 54.5%, and the usefulness rate was 50%.2) In 63.6% of the patients, its efficacy started within 2 weeks. In 50% of the remaining 36.4% patients, there was no response even after 8 weeks.3) Among the nasal symptoms, sneezing was reduced in 68.2%, and nasal obstruction in 63.2%. The relief of nasal obstruction was especially noteworthy.4) Among the objective symptoms, decreased nasal secretion was noted in 31.8%, and nasal discomfort in 28.6%. The number of eosinophils in the nasal discharge was decreased in 27.3%.5) The patients' diaries indicated marked reduction of nasal symptoms, such as frequency of sneezing attacks, frequency of nose blowing and nasal obstruction 2 to 3 weeks after the start of treatment.6) Side effects were reported in 30.4%, drowsiness in 21.7%.7) Blood tests showed no abnormalities.It is concluded that Ketotifen is clinically useful in the long-term treatment of perennial nasal allergy and is especially effective for nasal obstruction.
耳鼻咽喉科臨床学会の論文